FirstWord Group
LightNews LightNews
banner
firstwordgroup.com
FirstWord Group
@firstwordgroup.com
210 followers 35 following 1.3K posts
FirstWord is a global leader in news and intelligence for the Pharma and MedTech industries. Find our services here www.firstwordpharma.com, www.firstwordhealthtech.com, and www.firstwordreports.com
Posts Media Videos Starter Packs
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 9h
Merck & Co. starts building Virginia site, part of $70B in planned US investments $MRK firstwordpharma.com/story/6328430
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 11h
Neuphoria tanks after social anxiety drug flops in Phase III $NEUP firstwordpharma.com/story/6328411
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 11h
Samsung Bioepis expands into ADCs after separating from CDMO unit firstwordpharma.com/story/6328071
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 11h
AbbVie bolsters immunology hold as Rinvoq again edges out Humira $ABBV firstwordpharma.com/story/6328042
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 16h
Neuralink rival CoMind raises $60M to bring brain monitoring to the ICU firstwordhealthtech.com/story/6326250
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
ctDNA-guided chemotherapy shows promise in colon cancer trial #ESMO25 firstwordpharma.com/story/6327548
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
Summit to push lung cancer hopeful ivonescimab toward FDA without OS win $SMMT firstwordpharma.com/story/6326363
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
IDEAYA's darovasertib impresses in twin ocular cancer trials $IDYA firstwordpharma.com/story/6327486
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 1d
Exelixis shares fall as colorectal cancer drug hopeful shows mixed picture $EXEL #ESMO25 firstwordpharma.com/story/6326195
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 2d
Novo Nordisk's oral GLP-1 Rybelsus gets FDA green light for heart protection $NVO firstwordpharma.com/story/6325224
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 2d
Pluvicto slows progression of earlier-stage prostate cancer by 28% $NVS #ESMO25 firstwordpharma.com/story/6326042
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 2d
Vivace preps Phase III move for Hippo-targeting mesothelioma drug #ESMO25 firstwordpharma.com/story/6326025
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 2d
Bispecific ivonescimab beats PD-1 in China, setting stage for global test $SMMT $AKESF $MRK #ESMO25 firstwordpharma.com/story/6326043
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 2d
Datroway, Trodelvy deliver parallel wins in metastatic TNBC $AZN $DSNKY $GILD #ESMO25 firstwordpharma.com/story/6325267
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 3d
Padcev, Keytruda regimen given before, after surgery shines in bladder cancer $PFE $ALPMY $MRK #ESMO25 firstwordpharma.com/story/6324639
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 3d
Detailed data from Enhertu's dual wins in early-stage, HER2+ breast cancer $AZN $DSNKY #ESMO25 firstwordpharma.com/story/6324606
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Amgen, AstraZeneca's Tezspire snags rhinosinusitis FDA approval $AMGN $AZN firstwordpharma.com/story/6324607
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Trump's promise to slash Ozempic cost sinks shares of obesity drugmakers $NVO $LLY firstwordpharma.com/story/6323875
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Roche's Chugai inks $1.1B pact with Rani to move biologics beyond injections $RANI $RHHBY firstwordpharma.com/story/6323799
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 4d
Imfinzi cuts death risk by 22% in early gastric cancer $AZN #ESMO25 firstwordpharma.com/story/6323652
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
TrumpRx welcomes Merck KgaA, one of nine to receive new priority voucher firstwordpharma.com/story/6323519
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
AstraZeneca expands Immunai collaboration to tackle inflammatory bowel disease $AZN firstwordpharma.com/story/6323272
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
Dianthus bets up to $1B on Chinese biotech's autoimmune bifunctional $DNTH firstwordpharma.com/story/6323275
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
Veradermics raises $150M to finish late-stage studies of oral hair loss treatment firstwordpharma.com/story/6323223
firstwordgroup.com
FirstWord Group @firstwordgroup.com · 5d
Merck & Co. says Keytruda achieves full survival win in resistant ovarian cancer $MRK firstwordpharma.com/story/6322534